Hansoh Pharma reports 36% rise in first-half profit helped by innovative drug sales

• Net profit reached 4.26 billion yuan for the six months ended June 30, exceeding HSBC Qianhai Securities' forecast of 2.9 billion yuan
• Revenue from innovative medicines rose 15.4% to 7.09 billion yuan, now accounting for 85.4% of total revenue compared to 82.7% a year earlier
• Other income more than doubled to 1.32 billion yuan, boosted by gains from unlisted equity investments through life-science venture capital funds

Hansoh Pharma H1 2024 Summary

Key Financial Performance:

Hansoh Pharmaceutical Group, a Roche partner and China-based oncology and metabolic disease specialist, reported net profit of 4.26 billion yuan ($633.90 million) for the first half of 2024, representing a 35.8% increase from 3.13 billion yuan in the prior-year period. The results exceeded HSBC Qianhai Securities' forecast of approximately 2.9 billion yuan.

Revenue Drivers:

Innovative medicine sales rose 15.4% to 7.09 billion yuan, now comprising 85.4% of total revenue compared to 82.7% a year earlier. This shift underscores the company's strategic pivot toward higher-value proprietary drugs. Other income more than doubled to 1.32 billion yuan, boosted by gains from unlisted equity investments held through life-science venture capital funds.

Strategic Context:

The strong performance comes as Chinese drugmakers increasingly focus on innovative medicines amid Beijing's centralized bulk buying programs, which have pressured revenues from generic drugs. Hansoh has positioned itself aggressively in this space with over 70 clinical trials of innovative medicines underway as of last year.

Shareholder Returns:

The company declared an interim dividend of HK$0.285 ($0.0364) per share.

Market Implications:

Hansoh's results demonstrate successful adaptation to China's evolving pharmaceutical landscape, where innovation is becoming critical for growth. The company's partnership with Roche and substantial investment in drug development pipeline position it favorably in the competitive Chinese pharmaceutical market. The better-than-expected earnings suggest strong demand for specialized treatments in oncology and metabolic diseases.